Trial Profile
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Encoberminogene rezmadenovec (Primary)
- Indications Angina pectoris
- Focus Adverse reactions; First in man
- Acronyms EXACT
- Sponsors XyloCor Therapeutics
- 28 Aug 2023 Results of safety of XC001 administered via minimally invasive epicardial delivery , presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 25 Aug 2023 According to a XyloCor Therapeutics media release, results from phase 2 portion of this trial presented at the European Society of Cardiology (ESC) Congress 2023.
- 25 Aug 2023 Results from phase 2 portion of this trial presented in the XyloCor Therapeutics Media Release